Please login to the form below

Not currently logged in
Email:
Password:

Kala Pharmaceuticals

This page shows the latest Kala Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Latest appointments

  • Vedanta Biosciences appoints two new heads Vedanta Biosciences appoints two new heads

    Schopf formerly served as the senior director of preclinical development at Kala Pharmaceuticals and has over 20 years of industry experience.

  • ARC names chairman and member of the board ARC names chairman and member of the board

    Iwicki is executive chairman of the board of directors of Kala Pharmaceuticals and sits on the boards of Nimbus Therapeutics and Taris Biomedical.

  • Kala names Howard Rosen as chairman Kala names Howard Rosen as chairman

    Kala Pharmaceuticals has appointed life sciences industry veteran Howard Rosen as chairman of the board of directors. ... Kala's president and CEO Guillaume Pfefer commented on this rich experience when welcoming Rosen.

  • Allergan veteran joins Kala as head of business development Allergan veteran joins Kala as head of business development

    Charles McDermott has experience in ophthalmology. Charles McDermott, who has spent the last eight years at Allergan, has joined serious disease specialist Kala Pharmaceuticals as executive VP, business development. ... He also has research experience,

  • Kala Pharma appoints Fovea founder Bernard Gilly to board Kala Pharma appoints Fovea founder Bernard Gilly to board

    He previously formed the company that became Sanofi’s ophthalmology business. Dr Bernard Gilly, founder and CEO of Sanofi-owned Fovea, has joined the board of Kala Pharmaceuticals. ... He brings years of experience in eye treatment to Kala, which is

More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics